<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Whilst the interplay between type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) has been recognised for many years, recent analyses of existing studies have helped refine several aspects of this relationship with relevance to clinical practice </plain></SENT>
<SENT sid="1" pm="."><plain>First, recent data demonstrate that fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> is not linearly related to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk in those without <z:mp ids='MP_0002055'>diabetes</z:mp>; rather, risk levels escalate (modestly at first) only beyond specific <z:chebi fb="105" ids="17234">glucose</z:chebi> thresholds </plain></SENT>
<SENT sid="2" pm="."><plain>Consequently, <z:chebi fb="105" ids="17234">glucose</z:chebi>-based measures may not necessarily enhance <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk prediction in those without <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Second, other data confirm that new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> is not a post-<z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> 'risk equivalent' state and that, on average, several years of <z:mp ids='MP_0002055'>diabetes</z:mp> duration is needed to attain this level of risk </plain></SENT>
<SENT sid="4" pm="."><plain>Third, meta-analyses and systemic reviews have confirmed that <z:mp ids='MP_0002055'>diabetes</z:mp> increases <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk by around twofold on average and this risk is subject to wide variation, being lowest in those newly diagnosed and highest in those with existing <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e>, <z:hpo ids='HP_0000093'>proteinuria</z:hpo> or <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Fourth, meta-analyses of major <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering trials suggest that, whilst <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering lessens vascular risk, risk reduction arising from <z:chebi fb="0" ids="35664">statins</z:chebi> and blood pressure-lowering is greater </plain></SENT>
<SENT sid="6" pm="."><plain>Fifth, <z:chebi fb="0" ids="35664">statins</z:chebi> increase <z:mp ids='MP_0002055'>diabetes</z:mp> risk, albeit modestly, adding to the emerging concept that some agents that primarily target <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk may be diabetogenic, and vice versa </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, arising in part from the latter observation, as well as an understanding that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:mp ids='MP_0002055'>diabetes</z:mp> risk overlap in some individuals but not others, the case for combined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>/<z:mp ids='MP_0002055'>diabetes</z:mp> risk screening (generally using non-fasting <z:chebi fb="23" ids="18059">lipids</z:chebi> and HbA), has gained strength </plain></SENT>
</text></document>